scholarly journals Leuprolide Acetate 1-Month Depot for Central Precocious Puberty: Hormonal Suppression and Recovery

2010 ◽  
Vol 2010 ◽  
pp. 1-9 ◽  
Author(s):  
E. Kirk Neely ◽  
Peter A. Lee ◽  
Clifford A. Bloch ◽  
Lois Larsen ◽  
Di Yang ◽  
...  
Keyword(s):  
Precocious Puberty ◽  
Central Precocious Puberty ◽  
Leuprolide Acetate

Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: preliminary results

2009 ◽  
Vol 71 (5) ◽  
pp. 686-690 ◽  
Author(s):  
Verónica Mericq ◽  
Juan Javier Lammoglia ◽  
Nancy Unanue ◽  
Claudio Villaroel ◽  
María Isabel Hernández ◽  
...  
Keyword(s):  
Precocious Puberty ◽  
Central Precocious Puberty ◽  
Leuprolide Acetate ◽  
Preliminary Results

Monitoring treatment of central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation

2016 ◽  
Vol 0 (0) ◽  
Author(s):  
Peter A. Lee ◽  
Margaret Luce ◽  
Peter Bacher
Keyword(s):  
Luteinizing Hormone ◽  
Precocious Puberty ◽  
Central Precocious Puberty ◽  
Gonadotropin Releasing Hormone ◽  
Leuprolide Acetate ◽  
Open Label ◽  
Predictive Values ◽  
Post Hoc Analysis ◽  
Post Hoc ◽  
Monitoring Treatment

AbstractBackground:Peak gonadotropin-releasing hormone or agonist (GnRHa) stimulated luteinizing hormone (LH) testing with leuprolide acetate (LA) is commonly used to document suppression during therapy for central precocious puberty (CPP). The objective of the study was to investigate suitability of using basal LH levels to monitor GnRHa treatment and to determine optimal transition from 1-month to 3-month LA formulations via a post hoc analysis of a randomized, open-label, 6-month study.Methods:A total of 42 children with CPP, pretreated with 7.5-, 11.25-, or 15-mg 1-month LA formulations were randomized to 11.25- or 30-mg 3-month LA. Basal LH/peak-stimulated LH levels were measured at weeks 0, 4, 8 and 12. Positive/negative predictive values and sensitivities/specificities were determined for basal LH vs. LH-stimulation results.Results:Pretreatment with any 1-month formulation for the most part did not affect continuation of suppression after transitioning to 3-month formulation (mean peak-stimulated LH levels remained < 4 IU/L). Basal LH predicted suppression escape (basal LH-level cutoff ≥ 0.6 IU/L predicted 70% of those failing suppression). Tolerability was similar, regardless of dose.Conclusions:Our data indicate that a basal level of <0.60 IU/L is adequate for monitoring suppression approximately two-thirds of the time. Furthermore, the effectiveness and safety of 3-month LA treatments are not influenced by previous CPP therapies.

Sign in / Sign up

Export Citation Format

Share Document